Interferon gamma release assay
Interferon gamma release assay (IGRA) is a medical test used to detect infection with Mycobacterium tuberculosis, the bacterium that causes tuberculosis (TB). The test measures the immune system's response to TB bacteria by testing the patient's blood for the presence of interferon gamma, a type of cytokine that is released by T cells in response to infection.
Etymology
The term "interferon gamma release assay" is derived from the function of the test. "Interferon gamma" refers to the specific cytokine that the test measures, while "release assay" refers to the method of testing, which involves measuring the amount of interferon gamma released by T cells in response to TB bacteria.
Procedure
The IGRA test involves drawing blood from the patient and incubating it with antigens (substances that trigger an immune response) derived from M. tuberculosis. If the patient's immune system has been exposed to TB bacteria, the T cells in the blood sample will release interferon gamma. The amount of interferon gamma in the sample is then measured to determine whether the patient has a TB infection.
Types of IGRA
There are two types of IGRA tests: the QuantiFERON-TB Gold In-Tube test (QFT-GIT) and the T-SPOT.TB test. Both tests are approved by the U.S. Food and Drug Administration (FDA) for the detection of TB infection.
Interpretation
A positive IGRA result indicates that the patient's immune system has been exposed to TB bacteria. However, it does not distinguish between latent TB infection (LTBI) and active TB disease. Additional tests are needed to confirm the diagnosis and determine the stage of the disease.
Advantages and Limitations
IGRA tests have several advantages over the traditional tuberculin skin test (TST), including greater specificity and the need for only one patient visit. However, they also have limitations, such as the inability to distinguish between LTBI and active TB disease, and the potential for false-positive results in patients who have been vaccinated with the Bacillus Calmette-Guérin (BCG) vaccine.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


